Russ Trenary

Russ Trenary

Company: Outlook Therapeutics

Job title: President & Chief Executive Officer


Enhancing the Standard of Care in Wet AMD, BRVO, & DME 9:45 am

Outlook Therapeutics is attempting to achieve the first FDA approval in ophthalmology for Bevacizumab Outlook’s ONS 5010 meets standards required for FDA approval in ophthalmology not currently available by off label bevacizumab that is used on label for drip IV applications Data from the pivitol trial for ONS 5010 were outstanding and highly statistically significantRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.